XTL Biopharmaceuticals Acquires NeuroNOS to Enhance Autism Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy XTLB?
Source: Globenewswire
XTL Biopharmaceuticals Ltd. saw a pre-market price increase of 8.40% as it crossed above its 20-day SMA.
The company announced its acquisition of 85% of NeuroNOS for $32.5 million, aiming to develop disease-modifying therapies for autism. This strategic move brings together a renowned scientific team, including Nobel Laureates, and positions XTL to address a significant market gap, especially given the lack of FDA-approved therapies for autism. The acquisition also includes FDA orphan drug designations for NeuroNOS's products, ensuring market exclusivity and expedited review, which enhances their competitive edge.
This acquisition not only strengthens XTL's portfolio but also opens up substantial market opportunities in the autism treatment space, where demand is urgent and unmet.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XTLB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XTLB
About XTLB
X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XTL Biopharmaceuticals Acquires Psyga Bio to Expand into Psychedelic Medicine
- Acquisition Deal: XTL Biopharmaceuticals acquires Psyga Bio, gaining ownership of seven approved Phase 2 clinical trials focused on mental health, addiction, and neurological disorders, which is expected to accelerate drug development and enhance market competitiveness.
- Stock Surge: Following the acquisition announcement, XTLB shares surged over 90%, breaching the 200-day moving average for the first time since December 26, 2026, marking the largest single-day gain, indicating strong market optimism about its future prospects.
- Regulatory Support: The deal coincides with increasing regulatory support for psychedelic therapies in the U.S., as the FDA has introduced faster review pathways, which is expected to expand the use of psychedelic medicines for conditions like PTSD and depression, further driving industry growth.
- Investor Sentiment: Retail sentiment on Stocktwits shifted from neutral to ‘extremely bullish’, with message volumes spiking, and analysts noted that if the stock breaks above $4.30, significant upside potential is likely, reflecting strong market confidence in XTL's future.
See More
XTL Biopharmaceuticals Acquires Psyga Bio in Share-Based Deal
- Acquisition Overview: XTL Biopharmaceuticals (XTLB) has agreed to acquire 100% of Psyga Bio in a share-based transaction, where Psyga shareholders will receive shares representing 40% of XTL post-closing, indicating XTL's strong confidence in Psyga's future potential without cash consideration.
- Milestone Incentive Mechanism: An additional 10% equity may be issued upon achieving key clinical and commercialization milestones, which not only incentivizes the Psyga team to meet targets but also potentially enhances XTL's competitive position in the market.
- Technology and Resource Integration: Psyga brings a GMP-ready facility and a library of over 180 proprietary mushroom strains, which will provide robust technical support for XTL's planned seven Phase 2a clinical trials in mental health and CNS indications, thereby improving R&D efficiency.
- Funding Support and Market Reaction: XTL has secured a $1.5 million private placement to support the transaction, and XTLB shares rose 58.7% in premarket trading, reflecting positive market sentiment regarding the acquisition and optimistic expectations for the company's future growth.
See More
XTL Biopharmaceuticals Adjusts ADS Ratio to 1:400
- ADS Ratio Change: XTL Biopharmaceuticals will change its American Depositary Shares (ADS) ratio from 1:100 to 1:400 effective March 25, 2026, representing a 1-for-4 reverse ADS split for shareholders, which may alter the shareholder structure significantly.
- Cash Distribution Policy: The adjustment will not issue any fractional ADSs, with proceeds from fractional sales distributed in cash to shareholders, aiming to simplify the shareholder experience and reduce potential market volatility.
- Nasdaq Delisting Notice: XTL Biopharmaceuticals has received a delisting letter from Nasdaq, which could negatively impact the company's market image and shareholder confidence, further exacerbating investor concerns.
- Financial Disclosure: Despite facing delisting risks, XTL Biopharmaceuticals must continue to disclose its financial information promptly to ensure transparency and maintain investor trust, especially in the context of the ADS ratio adjustment.
See More
XTL Biopharmaceuticals Ltd. Announces Change in ADS Ratio from 1:100 to 1:400, Effective March 25, 2026
- Change in Ratio: The pharmaceutical company XTL Biopharma has announced a change in its stock ratio from 1:100 to 1:400.
- Effective Date: This change will take effect on March 25, 2026.
See More
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk
- Nasdaq Delisting Notice: XTL Biopharmaceuticals received a letter from Nasdaq indicating that it is considered a 'public shell', rendering the continued listing of its American Depositary Shares unwarranted, which poses significant financial and operational challenges for the company.
- Appeal Hearing Request: The company intends to request a hearing to contest the delisting process, and if successful, this request will stay the suspension of the ADSs pending the panel's decision, providing the company with crucial time to address its issues.
- Subsidiary Bankruptcy Filing: Nasdaq cited that XTL's wholly-owned subsidiary, The Social Proxy, has filed for insolvency in an Israeli court, which ordered liquidation and appointed a trustee on February 22, 2026, further exacerbating market concerns regarding the company's future viability.
- Insufficient Shareholder Equity: The company failed to meet the minimum $2.5 million shareholder equity requirement and was notified on December 20, 2025, that its ADSs were not in compliance with the minimum $1 bid price, and unless a hearing is requested by March 4, 2026, trading will be suspended on March 6, 2026.
See More
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk
- Nasdaq Delisting Notice: XTL Biopharmaceuticals received a notice from Nasdaq indicating the company is considered a 'public shell', with trading of its ADSs set to be suspended on March 6, 2026, unless a hearing is requested by March 4.
- Subsidiary Bankruptcy Impact: The company's wholly-owned subsidiary, The Social Proxy, has filed for bankruptcy, with a court order for liquidation issued on February 22, 2026, leading Nasdaq to conclude that XTL lacks an operating business, heightening delisting risks.
- Insufficient Shareholder Equity: XTL failed to meet the minimum $2.5 million shareholder equity requirement and its ADSs did not comply with the minimum $1 bid price rule, which Nasdaq cited as additional grounds for delisting, reflecting the company's precarious financial situation.
- Future Uncertainty: While the company intends to request a hearing to maintain its listing, there is no assurance that the panel will grant this request, leaving the future operational status and shareholder equity in significant uncertainty, which may undermine investor confidence.
See More
XTL Biopharmaceuticals Acquires Psyga Bio to Expand into Psychedelic Medicine
- Acquisition Deal: XTL Biopharmaceuticals acquires Psyga Bio, gaining ownership of seven approved Phase 2 clinical trials focused on mental health, addiction, and neurological disorders, which is expected to accelerate drug development and enhance market competitiveness.
- Stock Surge: Following the acquisition announcement, XTLB shares surged over 90%, breaching the 200-day moving average for the first time since December 26, 2026, marking the largest single-day gain, indicating strong market optimism about its future prospects.
- Regulatory Support: The deal coincides with increasing regulatory support for psychedelic therapies in the U.S., as the FDA has introduced faster review pathways, which is expected to expand the use of psychedelic medicines for conditions like PTSD and depression, further driving industry growth.
- Investor Sentiment: Retail sentiment on Stocktwits shifted from neutral to ‘extremely bullish’, with message volumes spiking, and analysts noted that if the stock breaks above $4.30, significant upside potential is likely, reflecting strong market confidence in XTL's future.
See More
XTL Biopharmaceuticals Acquires Psyga Bio in Share-Based Deal
- Acquisition Overview: XTL Biopharmaceuticals (XTLB) has agreed to acquire 100% of Psyga Bio in a share-based transaction, where Psyga shareholders will receive shares representing 40% of XTL post-closing, indicating XTL's strong confidence in Psyga's future potential without cash consideration.
- Milestone Incentive Mechanism: An additional 10% equity may be issued upon achieving key clinical and commercialization milestones, which not only incentivizes the Psyga team to meet targets but also potentially enhances XTL's competitive position in the market.
- Technology and Resource Integration: Psyga brings a GMP-ready facility and a library of over 180 proprietary mushroom strains, which will provide robust technical support for XTL's planned seven Phase 2a clinical trials in mental health and CNS indications, thereby improving R&D efficiency.
- Funding Support and Market Reaction: XTL has secured a $1.5 million private placement to support the transaction, and XTLB shares rose 58.7% in premarket trading, reflecting positive market sentiment regarding the acquisition and optimistic expectations for the company's future growth.
See More
XTL Biopharmaceuticals Adjusts ADS Ratio to 1:400
- ADS Ratio Change: XTL Biopharmaceuticals will change its American Depositary Shares (ADS) ratio from 1:100 to 1:400 effective March 25, 2026, representing a 1-for-4 reverse ADS split for shareholders, which may alter the shareholder structure significantly.
- Cash Distribution Policy: The adjustment will not issue any fractional ADSs, with proceeds from fractional sales distributed in cash to shareholders, aiming to simplify the shareholder experience and reduce potential market volatility.
- Nasdaq Delisting Notice: XTL Biopharmaceuticals has received a delisting letter from Nasdaq, which could negatively impact the company's market image and shareholder confidence, further exacerbating investor concerns.
- Financial Disclosure: Despite facing delisting risks, XTL Biopharmaceuticals must continue to disclose its financial information promptly to ensure transparency and maintain investor trust, especially in the context of the ADS ratio adjustment.
See More
XTL Biopharmaceuticals Ltd. Announces Change in ADS Ratio from 1:100 to 1:400, Effective March 25, 2026
- Change in Ratio: The pharmaceutical company XTL Biopharma has announced a change in its stock ratio from 1:100 to 1:400.
- Effective Date: This change will take effect on March 25, 2026.
See More
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk
- Nasdaq Delisting Notice: XTL Biopharmaceuticals received a letter from Nasdaq indicating that it is considered a 'public shell', rendering the continued listing of its American Depositary Shares unwarranted, which poses significant financial and operational challenges for the company.
- Appeal Hearing Request: The company intends to request a hearing to contest the delisting process, and if successful, this request will stay the suspension of the ADSs pending the panel's decision, providing the company with crucial time to address its issues.
- Subsidiary Bankruptcy Filing: Nasdaq cited that XTL's wholly-owned subsidiary, The Social Proxy, has filed for insolvency in an Israeli court, which ordered liquidation and appointed a trustee on February 22, 2026, further exacerbating market concerns regarding the company's future viability.
- Insufficient Shareholder Equity: The company failed to meet the minimum $2.5 million shareholder equity requirement and was notified on December 20, 2025, that its ADSs were not in compliance with the minimum $1 bid price, and unless a hearing is requested by March 4, 2026, trading will be suspended on March 6, 2026.
See More
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk
- Nasdaq Delisting Notice: XTL Biopharmaceuticals received a notice from Nasdaq indicating the company is considered a 'public shell', with trading of its ADSs set to be suspended on March 6, 2026, unless a hearing is requested by March 4.
- Subsidiary Bankruptcy Impact: The company's wholly-owned subsidiary, The Social Proxy, has filed for bankruptcy, with a court order for liquidation issued on February 22, 2026, leading Nasdaq to conclude that XTL lacks an operating business, heightening delisting risks.
- Insufficient Shareholder Equity: XTL failed to meet the minimum $2.5 million shareholder equity requirement and its ADSs did not comply with the minimum $1 bid price rule, which Nasdaq cited as additional grounds for delisting, reflecting the company's precarious financial situation.
- Future Uncertainty: While the company intends to request a hearing to maintain its listing, there is no assurance that the panel will grant this request, leaving the future operational status and shareholder equity in significant uncertainty, which may undermine investor confidence.
See More
